SINDCOMPOUND

Accelerate to the next phase

Commercializing the Difficult

Organometallics Compounds

Booth #617 February 2025

E N . S I N O C O M P O U N D . C O M



OUR MISSION

To help our customers identify, secure, and commercialize the **optimal catalyst technology** with confidence at every stage and scale from R&D to full-scale production.

COMPANY HISTORY



ABOUT SINOCOMPOUND

Organometallic Complexes and Homogeneous Catalysts

• Founded in 2008, 245 Employees

Global provider

• Fine Chemicals, Electronics and Petrochemicals industries

Proven process to Commercialize

- Expertise in organometallic synthesis
- R&D, Scale-up, and Manufacturing
- Robust EHS and quality systems

Established partnerships

• Academia and Industry



Where we are $\mathbf{9}$

Headquarters: Zhangjiagang, China

R&D Facilities: Suzhou & Zhangjiagang (10,000m²)

Manufacturing Site: Tongling (Expansion 2026)

Global Footprint: NA, EU, UK, India & China

Where our customers are 💡





STATE-OF-THE-ART FACILITIES

Zhangjiagang R&D

- 10,000m²
- Synthesis Labs
- Analytical Labs
- 50+ fume hoods
- 20+ 100L reactors
- 8 glove boxes
- LC, GC, ICP-MS, UV-Vis, external NMR



Tongling Plant, Anhui Province

- Commissioned Q3 2022
- Investment : \$30m
- 65,000m²
- 63 Reactors: 100L 3,000L
- Annual Capacity: 50 tons catalyst/ligands
- ISO9001
 ISO14001
 ISO45001



TONGLING PLANT PHASE I

Reactor Capacity – 50 metric tonnes

- 40 x 100-500L reactors
- 23 x 1000-3000L reactors

Reactor Materials of Construction & Capacities

- Stainless steel enameled with glass: 100L to 3000L
- Stainless steel lined with PTFE: 1000L
- Stainless steel: 100L, 500L, 1000L, 3000L

Cryogenic Capabilities

• -80 ° C to 160 ° C







TONGLING PLANT PHASE II

Hazardous Waste Furnace

Warehouse

2024 Completion



TONGLING PLANT PHASE II



Warehouse

Harzardous

Waste Furnace

Organometallic Manufacturing

SC



TONGLING PLANT - PHASE II

- Current Phase: Planning and Permits Application
- Next Phase:
 - Design: Q1-Q2 2025
 - Construction and installation begins Q3-Q4 2025
- Completion by Q4 2026
- Capacity increase from 50MT to 100MT



CATALYST MARKET

- **90%** of all commercially produced chemicals involve catalysis¹
- **70%** of Small Molecules involve Palladium catalysis²
- **60%** of FDA drugs approved in 2022 are Small Molecules³
- **Technology trend** in Non-platinum group catalysis⁴



¹https://onlinelibrary.wiley.com/doi/10.1002/anie.201509164, 2015
 ²https://www.technologynetworks.com/drug-discovery/news/novel-green-chemistry-method-improves-pharmaceutical-manufacturing-efficiency-297522, 2018
 ³https://www.ccdc.cam.ac.uk/discover/blog/fda-novel-drug-approvals-2022, 2022
 ⁴H. Zhao et al., ACS Catal. 2024, 14, 13, 9708–9733.



THE MANY BENEFITS OF CATALYSIS

- Facilitates new routes
- More efficient processes
- Shorter timelines
- Green Chemistry
- Drives cost reduction





DON'T LIMIT YOUR CATALYST SEARCH

Evolution of Catalysts



DON'T LIMIT YOUR CATALYST SEARCH

- Buchwald Ligands and Precatalysts*
- Mark Stradiotto Research Group*
- Keary Engle Scripps Research Group
- Dawei Ma Research Group*
- PGM and Non-PGM catalysts
- Catalyst Screening



PRODUCT PORTFOLIO

Non-platinum group metal catalysts

Cross-coupling catalysts







Ad₂P(*n*-Bu)

GPhos Pd G6 Br

Pd PtBu3 G6 Br



Dimethyl-cyclohexanediamine (Cu catalysis)

Latest additions



Ni(PPh₃)₂(naph)Cl

Chiral catalysts





DTBM-MeOBIPHEP



MeO-PyCam (Ni catalysis)



6-hydroxypicolinamide ligands (Cu catalysis)



Ni(COD)(tBu-BQ)

(RuCl[(R,R)-Tsdpen](p-cymene))

PRODUCT PORTFOLIO

Grubbs Series

Non-metallocenes





Grubbs II

Hoveyda-Grubbs II



(Ar-N=C(An)-C(An)=N-Ar)NiBr₂ (Ar = p-trifluoromethyl phenyl)



(Ar-N=C(Me)-C(Me)=N-Ar)Pd(Me)(Cl) (Ar = 2,6-diisopropyl phenyl)

Co-Catalyst

Bridged



Unbridged





 $(C_5H_4Me)_2TiCl_2$







 $[\]bar{\mathsf{B}(\mathsf{C}_6\mathsf{F}_5)_4}$

Bis(octadecyl)methylammonium tetrakis(pentafluorophenyl)borate

R¹ = H, Me, /Pr, etc. Ar = Ph, 4-tBuPh, etc.

DRIVE YOUR PROCESS COST DOWN



Don't dismiss technology that's currently not commercially available

- Reduce catalyst selection time
- Commercialize optimal catalyst
- Accelerate to the next phase



TIMELINES TO COMMERCIALIZATION





SELECTING THE RIGHT PARTNER

OPTIMAL CATALYST

- Advanced technology focus
- Collaboration/Partnering
- Rigorous IP due diligence
- Innovative manufacturing solutions
- Commercializing the difficult

Speed Quality Flexibility



SPECIALTY CHEMONINE.COM

SINOCOMPOUND

- Booth #617
- Our Offering
- Our Partner Philosophy

Commercialising the Difficult Homogeneous catalysts & ligands

Br

Dr Carin Seechurn Sinocompound, Associate Director Technology Solutions SINOCOMPOUND

Accelerate to the next phase

IN THIS ISSUE

 Cy_2

High Potency APIs - Contract Research & Toxicology - Supply Chain Management - Sustainability - Regulation & Compliance

SC

SINOCOMPOLIND



THANK YOU

Ruishan Chow <u>ruishan.chow@sinocompound.com</u>

en.sinocompound.com